Wednesday, August 26, 2020 8:54:29 AM
SAN DIEGO, Aug. 26, 2020 /PRNewswire/ -- Kintara Therapeutics, Inc. (formerly DelMar Pharmaceuticals, Inc.) ("Kintara" or the "Company") (Nasdaq: KTRA) announced today that Saiid Zarrabian, Chief Executive Officer of Kintara, will give a virtual corporate presentation at the LD Micro 500 taking place online on Thursday, September 3, 2020 at 4:00 PM ET followed by a live Q&A session with registered investors and other conference attendees.
Webcast link: https://www.webcaster4.com/Webcast/Page/2019/36846
In addition, Mr. Zarrabian will be available for virtual one-on-one meetings from September 1-4, 2020. To schedule a meeting please contact Eric Lahiji at mailto://eric@ldmicro.com.
About Kintara
Located in San Diego, California, Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs.
Kintara is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for glioblastoma multiforme (GBM) and REM-001 for cutaneous metastatic breast cancer (CMBC).
VAL-083 is a "first-in-class", small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian and other solid tumors (e.g. NSCLC, bladder cancer, head and neck) in U.S. clinical trials sponsored by the National Cancer Institute (NCI). Based on Kintara's internal research programs and these prior NCI-sponsored clinical studies, Kintara is currently conducting clinical trials to support the development and commercialization of VAL-083 in GBM.
Kintara is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications. REM-001 therapy, has been previously studied in four Phase 2/3 clinical trials in patients with CMBC, who had previously received chemotherapy and/or failed radiation therapy. With clinical efficacy to date of 80% complete responses of CMBC evaluable lesions and with an existing robust safety database of approximately 1,100 patients across multiple indications, Kintara is advancing the REM-001 CMBC program to late stage pivotal testing.
Forward-Looking Statements
This press release contains forward-looking statements based upon Kintara's current expectations. This communication contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by terminology such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other similar words. These statements are only predictions. Kintara has based these forward-looking statements largely on its then-current expectations and projections about future events, as well as the beliefs and assumptions of management. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Kintara's control, and actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: (i) risks associated with the impact of the COVID-19 pandemic; (ii) risks and uncertainties relating to Kintara's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of Kintara's products and technology; the availability of substantial additional funding for Kintara to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, Kintara's business, research, product development, regulatory approval, marketing and distribution plans and strategies (ii) whether the recently closed merger with Adgero Biopharmaceuticals will be successful, and (iii) those risks detailed in Kintara's most recent Annual Report on Form 10-K and subsequent reports filed with the SEC, as well as other documents that may be filed by Kintara from time to time with the SEC. Accordingly, you should not rely upon forward-looking statements as predictions of future events. Kintara cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. The forward-looking statements made in this communication relate only to events as of the date on which the statements are made. Except as required by applicable law or regulation, Kintara undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. Investors should not assume that any lack of update to a previously issued "forward-looking statement" constitutes a reaffirmation of that statement.
Contact Information
Investors:
CORE IR
516-222-2560
mailto://ir@coreir.com
Media:
Jules Abraham
Head of Public Relations
CORE IR
917-885-7378
mailto://julesa@coreir.com
View original content to download multimedia: http://www.prnewswire.com/news-releases/kintara-therapeutics-formerly-delmar-pharmaceuticals-to-present-at-the-ld-micro-500-virtual-conference-on-september-3rd-2020-301118619.html
SOURCE Kintara Therapeutics
Copyright 2020 PR Newswire
Recent KTRA News
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 09/20/2024 08:20:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/20/2024 08:15:07 PM
- Kintara Therapeutics Announces Adjournment of Special Meeting of Stockholders until October 4, 2024 • PR Newswire (US) • 09/20/2024 01:25:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 09/18/2024 12:40:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2024 12:35:07 PM
- Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences • PR Newswire (US) • 09/18/2024 12:30:00 PM
- Kintara Therapeutics Reminds Stockholders to Vote by Thursday to Allow for Completion of the Proposed Merger with TuHURA Biosciences • PR Newswire (US) • 09/18/2024 12:30:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 09/11/2024 12:40:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/11/2024 12:35:09 PM
- Kintara Therapeutics Provides Update on Corporate Developments and REM-001 Clinical Study • PR Newswire (US) • 09/11/2024 12:30:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 09/09/2024 08:10:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 08:05:10 PM
- Kintara Therapeutics to Hold Special Meeting of Stockholders to Allow for Completion of the Proposed Merger with TuHURA Biosciences, Inc. • PR Newswire (US) • 09/09/2024 12:30:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 09/03/2024 09:25:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/03/2024 09:20:24 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 08/19/2024 01:10:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 01:05:08 PM
- TuHURA Biosciences and Kintara Therapeutics Announce Kineta Inc. Reopens Enrollment for VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer • PR Newswire (US) • 08/19/2024 01:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/14/2024 04:15:13 AM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 08/12/2024 09:01:34 PM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 08/08/2024 09:30:36 PM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 07/19/2024 09:03:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/12/2024 09:17:26 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 07/08/2024 10:45:03 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 10:40:09 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM